Journal
PULMONARY CIRCULATION
Volume 12, Issue 2, Pages -Publisher
WILEY
DOI: 10.1002/pul2.12092
Keywords
ascites; epoprostenol; pulmonary hypertension
Ask authors/readers for more resources
The development of ascites in pulmonary arterial hypertension (PAH), without pre-existing hepatic dysfunction, is usually linked to decompensated right heart failure or cardiac cirrhosis. Ascites in PAH rarely occurs as a result of intravenous epoprostenol administration, a synthetic prostaglandin PGI(2).
The development of ascites in pulmonary arterial hypertension (PAH) in the absence of pre-existing hepatic dysfunction is usually associated with decompensated right heart failure or cardiac cirrhosis. Ascites in PAH has rarely been associated with intravenous epoprostenol, a synthetic form of the prostaglandin PGI(2).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available